

# Controlled Clinical Trials

## DESIGN, METHODS, AND ANALYSIS

---

*Official Journal of the Society for Clinical Trials*

### Volume 18, Number 1, 1997

RICHARD PETO, RORY COLLINS, DAVID SACKETT, JANET DARBYSHIRE, ABDEL BABIKER, MARC BUYSE, HELEN STEWART, MICHAEL BAUM, ARON GOLDBHIRSCH, GIANNI BONADONNA, PINUCCIA VALAGUSSA, LARS RUTQVIST, DIANA ELBOURNE, CHRISTINA DAVIES, OTILIA DALESIO, MAHESH PARMAR, CATHERINE HILL, MICHAEL CLARKE, RICHARD GRAY, AND RICHARD DOLL The Trials of Dr. Bernard Fisher: A European Perspective on an American Episode	1
JANET ADAMS, MYRNA SILVERMAN, DONALD MUSA, AND PAMELA PEELE Recruiting Older Adults for Clinical Trials	14
S.D. WALTER, DEBORAH J. COOK, GORDON H. GUYATT, DEREK KING, AND SUSAN TROYAN FOR THE CANADIAN LUNG ONCOLOGY GROUP Outcome Assessment for Clinical Trials: How Many Adjudicators Do We Need?	27
GERD ROSENKRANZ Can We Reduce the Dose of a Vaccine?	43
JON E. BLOCK Interpreting Studies of Exercise and Osteoporosis: A Call for Rigor	54
ANDRE BOUCKAERT AND RALPH CROTT The Difference in Mean Costs as a Pharmacoeconomic Outcome Variable: Power Considerations	58
MARIKA IWANE, JOLIE PALENSKY, AND KATHRYN PLANTE A User's Review of Commercial Sample Size Software for Design of Biomedical Studies Using Survival Data	65
<b>Book Reviews</b>	84
<b>Books Reviewed</b>	90
<b>Erratum</b>	90
<b>List of Reviewers</b>	91
<b>Design Paper</b> MIKKO SYVÄNNE, MARJA-RITTA TASKINEN, MARKKU S. NIEMINEN, VESA MANNINEN, Y. ANTERO KESÄNIEMI, AMOS PASTERNAK, JAMES W. NAWROCKI, HARRY HABER, AND M. HEIKKI FRICK A Study to Determine the Response of Coronary Atherosclerosis to Raising Low High Density Lipoprotein Cholesterol with a Fibrin-Acid Derivative in Men after Coronary Bypass Surgery: The Rationale, Design, and Baseline Characteristics of the LOCAT Study	93

### Volume 18, Number 2, 1997

ANDREW R. WILLAN, BERNIE J. O'BRIEN, AND DEBORAH J. COOK Benefit-Risk Ratios in the Assessment of the Clinical Evidence of a New Therapy	121
---	-----

LAURENCE S. FREEDMAN, MITCHELL H. GAIL, SYLVAN B. GREEN, AND DONALD K. CORLE FOR THE COMMIT RESEARCH GROUP	
The Efficiency of the Matched-Pairs Design of the Community Intervention Trial for Smoking Cessation (COMMIT)	131
TIINA HOKKANEN, ELINA HEMMINKI, PIRJO AALTO, MATTI HAKAMA, HEINI HUHTALA, MARJA JYLHÄ, SAKARI KARJALAINEN, AND RISTO TUIMALA	
Patient Managed Clinical Trial	140
THEODORE G. KARRISON	
Use of Irwin's Restricted Mean as an Index for Comparing Survival in Different Treatment Groups—Interpretation and Power Considerations	151
WENDY J. MACK, STANLEY P. AZEN, MELEANA DUNN, AND HOWARD N. HODIS	
A Comparison of Quantitative Computerized and Human Panel Coronary Endpoint Measures: Implications for the Design of Angiographic Trials	168
LANCE A. WALLER	
A Note on Harold S. Diehl, Randomization, and Clinical Trials	180
<b>Software Review</b>	184
<b>Erratum</b>	185
 <b>Volume 18, Number 3, 1997</b>	
BERNARD VRIJENS AND ELS GOETGHEBEUR	
Comparing Compliance Patterns Between Randomized Treatments	187
Ji ZHANG, HUI QUAN, JENNIFER NG, AND MICHAEL E. STEPANAVAGE	
Some Statistical Methods for Multiple Endpoints in Clinical Trials	204
PETER C. O'BRIEN, AND NANCY L. GELLER	
Interpreting Tests for Efficacy in Clinical Trials With Multiple Endpoints	222
KAREN SUCHANEK HUDMON, ROBERT M. CHAMBERLAIN, AND RALPH F. FRANKOWSKI	
Outcomes of a Placebo Run-in Period in a Head and Neck Cancer Chemoprevention Trial	228
LISA J. MARTIN, GINA A. LOCKWOOD, ALAN R. KRISTAL, VALENTINA KRIUKOV, CAROLYN GREENBERG, ANN L. SHATUCK, AND NORMAN F. BOYD	
Assessment of a Food Frequency Questionnaire as a Screening Tool for Low Fat Intakes	241
NICOLE URBAN, CHARLES DRESCHER, RUTH ETZIONI, AND CHRIS COLBY	
Use of a Stochastic Simulation Model to Identify an Efficient Protocol for Ovarian Cancer Screening	251
<b>Book Review</b>	271
<b>Letter to the Editor</b>	274
 <b>Volume 18, Number 3S, 1997</b>	
<b>Supplement</b>	
Letter from the President	1S
Calendar of Program	4S
Abstracts: Second Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics	41S
Author Index	191S

**Volume 18, Number 4, 1997**

**Quality of Life in Comparative Cancer Clinical Trials**

- EDWARD L. KORN  
Assessing Quality of Life in Comparative Cancer Clinical Trials:  
Does It Make a Difference? 275
- CHARLES B. SCOTT  
Quality-Adjusted Survival Analysis of Malignant Glioma Patients 277
- JAMES E. HERNDON II, STEWART FLEISHMAN, MICHAEL P. KOSTY,  
AND MARK R. GREEN  
A Longitudinal Study of Quality of Life in Advanced Non-Small Cell Lung Cancer:  
Cancer and Leukemia Group B (CALGB) 8931 286
- DAVID MACHIN  
Assessing Quality of Life in Comparative Cancer Clinical Trials:  
Does It Make a Difference? 301
- SYLVAN B. GREEN  
Does Assessment of Quality of Life in Comparative Cancer Trials Make  
a Difference? A Discussion 306
- CAROL M. MOINPOUR  
Do Quality of Life Assessments Make a Difference in the Evaluation of  
Cancer Treatments? 311

**Original Articles**

- PAUL L. CANNER, BRUCE THOMPSON, GENELL L. KNATTERUD,  
NANCY GELLER, LUCIEN CAMPEAU, AND DAVID ZUCKER  
An Application of the Zucker-Wittes Modified Ratio Estimate Statistic in the  
Post Coronary Artery Bypass Graft (CABG) Clinical Trial 318
- LAURA C. LOVATO, KRISTIN HILL, STEPHANIE HERTERT,  
DONALD B. HUNNINGHAKE, AND JEFFREY L. PROBSTFIELD  
Recruitment for Controlled Clinical Trials: Literature Summary and  
Annotated Bibliography 328

**Design Paper**

- HAROLD P. ADAMS, JR., ROBERT F. WOOLSON, WILLIAM R. CLARKE,  
PATRICIA H. DAVIS, BIRGITTE H. BENDIXEN, BETSY B. LOVE,  
PATRICIA A. WASEK, AND KARLA J. GRISMAN  
Design of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 358

**Software Review 378**

**Letters to the Editor**

- LESLIE A. KALISH AND HENRY A. FELDMAN  
Number of Phone Lines for Telephone Randomization 380
- PETER A. LACHENBRUCH  
The Odds Ratio 381

**Volume 18, Number 5, 1997**

- THEODORE C. MORRISON, DENNIS R. WAHLGREN, MELBOURNE F. HOVELL,  
JOY ZAKARIAN, SUSAN BURKHAM-KREITNER, C. RICHARD HOFSTETTER,  
DONALD J. SLYMEN, KRISTEN KEATING, STERGIOS RUSSOS,  
AND JENNIFER A. JONES  
Tracking and Follow-Up of 16,915 Adolescents: Minimizing Attrition Bias 383

PETER PEDUZZI, SAM DONTA, AND MARIKA IWANE A Review of the Design of Vaccine Efficacy Trials and a Proposal for the Design of the VA Cooperative Study of Active Immunotherapy of HIV Infection	397
ROBERT P. McMAHON, MYRON A. WACLAWIW, NANCY L. GELLER, FRANCA B. BARTON, MICHAEL L. TERRIN, AND DUANE R. BONDS An Extension of Stochastic Curtailment for Incompletely Reported and Classified Recurrent Events: The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH)	420
JOHN P.A. IOANNIDIS, JOSEPH C. CAPPELLERI, HENRY S. SACKS, AND JOSEPH LAU The Relationship between Study Design, Results, and Reporting of Randomized Clinical Trials of HIV Infection	431
WEN-MIIN LIANG AND MORTON B. BROWN A Median-Based Test Under Informative Dropout: The One-Sample Case	445
<b>Book Reviews</b>	460
<b>Design Paper</b>	
PAUL P. GLASZIOU, R. JOHN SIMES, JANE HALL, AND CAM DONALDSON, ON BEHALF OF THE LIPID STUDY GROUP Design of a Cost-Effectiveness Study within a Randomized Trial: The LIPID Trial for Secondary Prevention of IHD	464
 <b>Volume 18, Number 6, 1997</b>	
<b>Papers from the Eighth International Symposium on Long-Term Clinical Trials</b>	
<b>Guest Editors: Salim Yusuf, Michael Gent, Genell Knatterud, and Michael Terrin</b>	
SALIM YUSUF, MICHAEL GENT, GENELL KNATTERUD, AND MICHAEL TERRIN Introduction	477
<b>Surgical and Device Trials</b>	
HENRY BUCHWALD Surgical Procedures and Devices Should Be Evaluated in the Same Way as Medical Therapy	478
JOHN W. KIRKLIN, EUGENE H. BLACKSTONE, DAVID C. NAFTEL, AND MALCOLM E. TURNER Influence of Study Goals on Study Design and Execution	488
<b>Lifestyle Modification</b>	
MEIR STAMPFER Observational Epidemiology Is the Preferred Means of Evaluating Effects of Behavioral and Lifestyle Modification	494
MICHAEL L. TERRIN Individual Subject Random Assignment Is the Preferred Means of Evaluating Behavioral Lifestyle Modification	500
SYLVAN B. GREEN The Advantages of Community-Randomized Trials for Evaluating Lifestyle Modification	506
GENELL L. KNATTERUD DISCUSSION: Why Clinical Trials in the Evaluation of Life Style Evaluation?	514
<b>Multiple Outcomes</b>	
CHRISTOPHER P. CANNON Clinical Perspectives on the Use of Composite Endpoints	517

STUART J. POCOCK	
Clinical Trials with Multiple Outcomes: A Statistical Perspective on their Design, Analysis, and Interpretation	530
MICHAEL GENT	
DISCUSSION: Some Issues in the Construction and Use of Clusters of Outcome Events	546
<i>Secondary Endpoints</i>	
ROBERT T. O'NEILL	
Secondary Endpoints Cannot Be Validly Analyzed if the Primary Endpoint Does Not Demonstrate Clear Statistical Significance	550
C.E. DAVIS	
Secondary Endpoints Can Be Validly Analyzed, Even if the Primary Endpoint Does Not Provide Clear Statistical Significance	557
ROSS L. PRENTICE	
DISCUSSION: On the Role and Analysis of Secondary Outcomes in Clinical Trials	561
<i>When Is the Evidence Compelling from Clinical Trials or their Meta-Analyses?</i>	
MARCUS D. FLATHER, MICHAEL E. FARKOUH, JANICE M. POGUE, AND SALIM YUSUF	
Strengths and Limitations of Meta-Analysis: Larger Studies May Be More Reliable	568
JANICE M. POGUE AND SALIM YUSUF	
Cumulating Evidence from Randomized Trials: Utilizing Sequential Monitoring Boundaries for Cumulative Meta-Analysis	580
SALIM YUSUF	
Meta-Analysis of Randomized Trials: Looking Back and Looking Ahead	594
<i>Societal, Ethical and Regulatory Issues in Clinical Trials: When Are Clinical Trials of a Given Agent or Class of Agent vs. Placebo No Longer Appropriate or Feasible?</i>	
BARUCH A. BRODY	
When Are Placebo-Controlled Trials No Longer Appropriate?	602
ROBERT J. TEMPLE	
When Are Clinical Trials of a Given Agent vs. Placebo No Longer Appropriate or Feasible?	613
<i>Approaches to Informed Consent</i>	
GIANNI TOGNONI AND ENRICO GERACI	
Approaches to Informed Consent	621
SUSAN S. ELLENBERG	
Informed Consent: Protection or Obstacle? Some Emerging Issues	628
<i>Errors, Misunderstandings, and Fraud</i>	
DAVID L. DeMETS	
Distinctions between Fraud, Bias, Errors, Misunderstanding, and Incompetence	637
ROBERT M. CALIFF, SHARON L. KARNASH, AND LYNN H. WOODLIEF	
Developing Systems for Cost-Effective Auditing of Clinical Trials	651
GEORGE W. WILLIAMS	
DISCUSSION: Errors, Misunderstandings, and Fraud	661
Volume 18 Author Index	667
Volume 18 Subject Index	669
Volume Contents	